Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14877MR)

This product GTTS-WQ14877MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14877MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15894MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ3777MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ2902MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ1446MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ14111MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ3788MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ368MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ15094MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW